Follow
Megan D. Hoban
Megan D. Hoban
Scientist, Magenta Therapeutics
Verified email at ucla.edu
Title
Cited by
Cited by
Year
Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells
MD Hoban, GJ Cost, MC Mendel, Z Romero, ML Kaufman, AV Joglekar, ...
Blood 125 (17), 2597-2604, 2015
3382015
Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease
MD Hoban, SH Orkin, DE Bauer
Blood 127 (7), 839-848, 2016
1692016
Wild-type adenoviruses from groups A–F evoke unique innate immune responses, of which HAd3 and SAd23 are partially complement dependent
DM Appledorn, A Kiang, A McBride, H Jiang, S Seregin, JM Scott, ...
Gene therapy 15 (12), 885-901, 2008
582008
A genome editing primer for the hematologist
MD Hoban, DE Bauer
Blood 127 (21), 2525-2535, 2016
352016
Dissecting the Mechanism of Histone Deacetylase Inhibitors to Enhance the Activity of Zinc Finger Nucleases Delivered by Integrase-Defective Lentiviral Vectors
AV Joglekar, L Stein, M Ho, MD Hoban, RP Hollis, DB Kohn
Human gene therapy 25 (7), 599-608, 2014
212014
CRISPResso: sequencing analysis toolbox for CRISPR genome editing
L Pinello, MC Canver, MD Hoban, SH Orkin, DB Kohn, DE Bauer, ...
bioRxiv, 031203, 2016
182016
The human ankyrin 1 promoter insulator sustains gene expression in a β-globin lentiviral vector in hematopoietic stem cells
Z Romero, B Campo-Fernandez, J Wherley, ML Kaufman, F Urbinati, ...
Molecular Therapy-Methods & Clinical Development 2, 15012, 2015
162015
Delivery of genome editing reagents to hematopoietic stem/progenitor cells
MD Hoban, Z Romero, GJ Cost, M Mendel, M Holmes, DB Kohn
Current protocols in stem cell biology, 5B. 4.1-5B. 4.10, 2016
102016
The system can't perform the operation now. Try again later.
Articles 1–8